Skip to main content

Allergic Rhinitis Due to House Dust Mite

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Syneos Health
Syneos HealthNC - Morrisville
1 program
1
500 IR house dust mites allergen extract tabletPhase 11 trial
Active Trials
NCT01919554Completed37Est. Sep 2013
Stallergenes Greer
Stallergenes GreerFrance - Antony
2 programs
500 IR house dust mites allergen extract tabletPHASE_1
100 IR house dust mites allergen extract tabletPHASE_21 trial
Active Trials
NCT01527188Completed355Est. Sep 2012
Allergopharma
AllergopharmaGermany - Reinbek
1 program
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot N/A1 trial
Active Trials
NCT07096440Not Yet Recruiting105Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stallergenes Greer100 IR house dust mites allergen extract tablet
Syneos Health500 IR house dust mites allergen extract tablet
AllergopharmaNoninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot

Clinical Trials (3)

Total enrollment: 497 patients across 3 trials

NCT01527188Stallergenes Greer100 IR house dust mites allergen extract tablet

Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Start: Dec 2010Est. completion: Sep 2012355 patients
Phase 2Completed
NCT01919554Syneos Health500 IR house dust mites allergen extract tablet

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

Start: Jul 2013Est. completion: Sep 201337 patients
Phase 1Completed
NCT07096440AllergopharmaNoninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot

Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites

Start: Jul 2025Est. completion: Jun 2026105 patients
N/ANot Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.